246
10. Arias TD, Jorge LF, Inaba T. No evidence for the
present of poor metabolizers of sparteine in an
Amerindian group. Br J Clin Pharmac, 21, 547-549,
1986.
11. Arunkumar Shastri R. Undernourrished adults and
acetylation phenotype. Int J Clin Pharmacol Ther
Toxicol. 20r 194-196, 1982.
12. Arvela P, Kirjarinta M, Krki N, Pelkonen O.
Polymorphism of debrisoquine hydroxylation among Finns
and Lapps. Br J Clin Pharmacol, 26, 601-603, 1988.
13. Azad Khan AK, Nurazzaman M, Truelove SC. The effect of
the acetylator phenotype on the metabolism of
suphasalazine in man. J Med Genetics. 20, 30-36,
1983.
14. Balant-Gorgia AE, Schulz P, Dayer P, Balant L, Kubli
A, Gertsch C, Garrone G. Role of oxidation
polymorphism on blood and urine concentrations of
247
amitriptyline and its metabolites in man. Arch
Psvchiat Neurol Sci. 232. 215-222, 1982.
15. Bamrah JS, Soni SD. Drug-induced Parkinson's disease.
Lancet. 1, 1031-1032, 1987.
16. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S,
Poirier J. Ecogenetics of Parkinson's disease:
4-hydroxylation of debrisoquine. Lancet, 2.,
1213-1216, 1985.
17. Barclay WR, Ebert RH, Le Roy GV, Manthei RW, Roth LJ.
Distribution and excretion of radioactive isoniazid in
tuberculous patients. JAMA. 151. 1384-1388, 1953.
18. Batchelor JR, Welsh KI, Mansilla-Tinoco R, Collery CT,
Hughes GRV, Bernstein R, Ryan P, Naish PF, Abler GM,
Bing RF, Russell GI. Hydralazine-induced systemic lupus
erythematosus: Influence of HLA-DR and sex on
susceptibility.. Lancet, 1, 1107-1109, 1980.
248
19. Benítez J, Llerena A, Cobaleda J. Debrisoquin
oxidation polymorphism in a Spanish population. Clin
Pharmacol Therf 44f 74-77, 1988.
20. Bertilsson L, Aberg-Wistedt A. The debrisoquine
hydroxylation test predicts steady-state plasma levels
of desipramine. Br J Clin Pharmacol, 15, 388-390,
1983.
21. Bertilsson L, Dengler HJ, Eichelbaum M, Schultz HU.
Pharmacogenetic covariation of defective N-oxidation
of sparteine and 4-hydroxylation of debrisoquine. Eur
J Clin Pharmacol. 17. 153-155, 1980.
22. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J,
Schultz HU, Sjqvist F. Nortriptyline and antipyrine
clearance in relation to debrisoquine hydroxylation
in man. Life Sci. 27. 1673-1677, 1980.
23. Bienzle U. Glucose-6-phosphate dehydrogenase
deficiency. Part I: Tropical Africa. Clin Haematolf
10, 785-799, 1981.
249
24. Blain PG, Mucklow JC, Wood P, Roberts DF, Rawlins MD.
Family study of antipyrine clearance. Br Med J,
284, 150-152, 1982.
25. Bloom, GE, Zarkowsky HS. Heterogeneity of the
enzymatic defect in congenital methemoglobinemia.
N Enql J Med. 281. 919, 1969.
26. Bodansky HJ, Drury PL, Cudworth AG, Price Evans DA.
Acetylator phenotypes and type I (insulin-dependent)
diabetics with microvascular disease. Diabetes.
10, 907-910, 1981.
27. Boobis AR, Murray S, Khan GC, Robertz G-M, Davies DS.
Substrate specificity of the form of cytochrome P-450
catalyzing the 4-hydroxylation of debrisoquine in man.
Mol Pharmacol. 23. 471-481, 1983.
28. Breimer DD. Interindividual variations in drug
disposition: clinical implications and methods of
investigation. Clin Pharmacokin. 8., 371-377, 1983.
250
29. Brosen K, Otton SV, Gram LF. Spartein oxidation
polymorphism in Denmark. Acta Pharmacol Toxicol. 57,
357-360, 1985.
30. Brosen K, Gram LF. Clinical significance of the sparteine/
debrisoquine oxydation polymorphism. Eur J Clin Pharmacol,
16, 537-547, 1989.
31. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA,
Pavlova MV. Acetylator phenotype in patients with
breast cancer. Oncologyf 35, 185-188, 1978.
32. Burns RS, Markey SP, Philips JM, Chilich CC. The
neurotoxicity of l-methyl-4-phenyl-l-l,2,3,6-
-tetrahydropyridine in the monkey and man. Can J
Neurol Sci. 11 fsuppl). 166-169, 1984.
33. Burrows AW, Hockaday TDR, Mann JI, Taylor JG. Diabetic
dimorphism according to acetylator status. Br Med J.
1, 208-210, 1978.
251
34. Calne DB, Bisen A, McGeer E, Spencer P. Alzheimer's
disease, Parkinson's disease, and motoneurone disease:
abiotropic interaction between ageing and
environment?. Lancet. 2, 1067-1070, 1986.
35. Calne DB, Langston JW. Aetiology of Parkinson's
disease. Lancet. 2, 1457-1459, 1983.
36. Cartwright RA, Glashen RW, Rogers HJ, Ahmad RA,
Barham-Hall D, Higgins E, Kahn MA. Role of
N-acetyltransferase phenotypes in bladder
carcinogenesis: a pharmacogenetic epidemiological
approach to bladder cancer. Lancet, 2., 842-845,
1982.
37. Chapman CJ. Drugs and genes: therapeutic implications,
Drugs. 14, 120-127, 1977.
38. Champman LJ, Peters HA, Matthews CG, Levine RL.
Parkinsonism and industrial chemicals. Lancet, JL,
332-333, 1987.
252
I .
39. Chapron DJ, Blum MR. Relationship of sulphamethazine
disposition kinetics to acetylator phenotype in man.
J Clin Pharmacol. 16, 338-344, 1976.
40. Chapron DJ, Kramer PA, Mercik SA. Potential influence
of body weight on the clearance of polymorphically
acetylated drugs. J Clin Pharmacol. 22, 271-275,
1982.
41. Clark DWJ. Simultaneous phenotyping for oxidation and
acetylation status. Proceedings of the University of
Otago Medical School Dunedin NZ. 61, 30-32, 1983.
42. Clark DWJ, Blain PG, Rawlins MD, Roberts DH.
Pharmacogenetic screening in the general population.
(Abstract). Clin Exp Pharmacol Phvsiolf Suppl 8,
67, 1984.
43. Clark DWJ, Morgan A, Waal-Manning H. Adverse effects
from metoprolol are not generally associated with
oxidation status. Br J Clin Pharmacol. 18, 965-967, 1985,
253
44. Clark DWJ. Genetically determined variability in
acetylation and oxidation. Therapeutic implications.
Drugs. 29, 342-375, 1985.
45. Clark DWJ, Edwards IR. Adverse drug reaction reporting
and retrospective phenotyping for oxidation
polymorphism. Med Toxicol. 3., 241-247, 1988.
46. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME.
Methemoglobinemia provoked by malarial
chemoprophylaxis in Vietnam. N Engl J Medf 279,
1127-1131, 1968.
47. Coombes RC, Foster AB, Harland SJ, Jarman M, Nice EC.
Polymorphically acetylated aminoglutethimide in
humans. Br J Cancer, 46P 340-345, 1982.
48. Cooper RG, Price Evans DA, Whibley EJ. Polymorphic
hydroxylation of perhexiline maléate in man. J Med
Genetics, .21, 27-33, 1984.
254
49. Cowan GO, Das KM, Eastwood MA. Further studies of
sulphasalazine metabolism in the treatment of
ulcerative colitis. Br Med J. 2, 1057-1059, 1977.
50. Danhof M, de Groot-van der Vis E, Breimer DD. Assay of
antipyrine and its primary metabolites in plasma,
saliva and urine by high-performance liquid
chroraatography with some preliminary results in man.
Pharmacology, 18. 210-223, 1979.
51. Danhof M, Idle JR, Teunissen NWE, Sloan TP, Breimer
DD, Smith RL. Influence of the genetically controlled
deficiency in debrisoquine hydroxylation on antipyrine
metabolite formation. Pharmacology, 22, 349-358,
1981.
52. Davidson J, Me Leod NN, Blum MR. Acetylation phenotype,
platelet raonoamine oxydase inhibition, and the
effectiveness of phenelzine in depression. Am J Psychiat,
135f 467-469, 1978.
255
53. Davies DS, Beedie MA, Rawlins MD. Antinuclear
antibodies during procainamide treatment and drug
acetylation. Br Med J, 3., 682-683, 1975.
54. Davies DS, Boobis AR. Variants of human microsomal
enzymes. Biochem Soc Transactions, II, 459-460,
1983.
55. Davis GC, Williams AC, Markey SP, et al. Chronic
parkisonism secondary to intravenous injection of
meperidine analogues. Psychiat Res. I, 249-254,
1979.
56. Dayer P, Balant L, Kupfer A, Courvoisier F, Fabre J.
Contribution of the genetic status of oxidative
metabolism to variability in the plasma concentrations
of beta-adrenoceptor blocking agents. Eur J Clin
Pharmacol. 24., 797-799, 1983.
j 57. Dayer P, Courvoisier F, Balant L, Fabre J.II Beta-blockers and drug oxidation status. Lancetfí
1, 509, 1982.
256
58. Dayer P, Leemannt T, Marmy A, Rosenthaler J.
Interindividual variation of beta-adrenoreceptor
blocking drugs, plasma concentration and effect:
influence of genetic status on behaviour of atenolol,
bopindol and metoprolol. Eur J Clin Pharmacolf 28.
149-153, 1985.
59. De Lúea HF, Suttie JW (eds). The Fat soluble vitamins,
University of Wisconsin Press. Madison, 1970.
60. De Matteis F. Disturbances of liver porphyrin
metabolism caused by drugs. Pharmacol Revf 19.
523-557, 1967.
61. de Wolff FA, Vermeij P, Ferrari MD, Buruma OJS,
Breimer DD. Impairment of phenytoin parahydroxylation
as a cause of severe intoxication. Ther Drug Monit,
5, 213-215, 1983.
62. Devadatta S, Gangadharan PRJ, Andrews RH, Fox W,
Ramakrishnan CV, Shelon JB, Veru S. Peripheral
neuritis due to isoniazid. Bull World Health
257
Organization, 23, 587-598, 1960.
63. Dickinson DS, Bailey WC, Hirschowitz DI, Soong SJ,
Eidus L, Hodking MM. Risk factors for isoniazid
(INH)-induced liver dysfunction. J Clin
Gastroenterol. 3., 271-279, 1981.
64. Drayer DE, Reidenberg MM. Clinical consequences of
polymorphic acetylation of basic drugs. Clin
Pharmacol Ther. 22. 251-258, 1977.
65. Drayer DE, Reidenberg MM, Sevy RW.
N-acetylprocainamide: an active metabolite of
procainamide. Proc Soc Exp Biol Med, 146. 358-363,
1974.
66. Drayer P, Leeman T, Striberni R. Dextrometorphan
0-demethylation in liver microsomes as a prototype
to monitor cytocrome P450 dbl activity. Clin Pharmacol
:, 45. 34-40, 1989.
67. du Souich P, Lalka D, Slaughter R, Elvin AT, McLean
258
AJ. Mechanisms of non-linear disposition kinetics of
sulphamethazine. Clin Pharmacol Ther, 25, 172-183, 1979
68. du Souich P, McLean AJ, Stoeckel K, Ohlendorf D,
Gibaldi M. Screening methods using suphamethazine for
determining acetylator phenotype. Clin Pharmacol
Ther, 26. 757-765, 1979.
69. Ehrenfeld N, Zylber-Katz E, Levy M. Acetylator
phenotype in rheumatoid arthritis. Israel J Med Sci,
19. 368-379, 1983.
70. Eichelbaum M. Defective oxidation of drugs:
pharmacokinetic and therapeutic implications. Clin
Pharmacokin, 7_, 1-22, 1982.
71. Eichelbaum M, Bertilsson L, Sawe J. Antipyrine
metabolism in relation to polymorphic oxidations of
sparteine and debrisoquine. Br J Clin Pharmacol,
15, 317-321, 1983.
\
259
72. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C.
Polymorphic oxidation of sparteine and debrisoquine:
related pharmacogenetic entities. Clin Pharmacol
Ther. 31, 184-186, 1982.
73. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ.
Defective N-oxidation of sparteine in man: a new
pharmacogenetic defect. Eur J Clin Pharmacolf 16.
183-187, 1979.
74. Eichelbaum M, Woolhouse NM. Inter-ethnic differences in
sparteine oxydation among Ghanaians and Germans. Eur
Clin Pharmacol, 28. 79-83, 1985.
75. Eidus L, Harnanansingh HM, Jessamine AG. Urine test
for phenotyping isoniazid inactivators. Am Rev Respir
Pis. 104. 587, 1971.
76. Eidus L, Ling GM, Harnanansingh AMT. Isoniazid
excretion in fast and slow inactivators and its
practical aspect for phenotyping. Arzneimittel-
Forschuna. 21. 1696-1699, 1971.
269
77. Ellard GA. Variations between individuals and
populations in the acetylation of isoniazid and its
significance for the treatment of pylmonary tuberculosis,
Clin Pharmacol Ther. 19. 610-625, 1976.
78. Ellard GA, Gammon PT. Acetylator phenotyping of
tuberculosis patients using matrix isoniazid or
sulphadimidine and its prognostic significance for
treatment. Br J Clin Pharmacolf 4_, 5-14, 1977.
79. Elson J, Strong JM, Atkinson Jr AJ. Antiarrythmic
potency of N-acetylprocainamide. Clin Pharmacol
Ther. 17. 134-140, 1975.
80. Erdtmansky P, Goelh TJ. Gas-liquid chromatographic
electron capture determination of some monosubstituted
guanido-containing drugs. Analytical Chemistryf
47. 750-752, 1975.
81. Farah F, Taylor W, Rawlins MD, James O. Hepatic drug
acetylation and oxidation: effects of ageing in man.
Br Med J. 2, 155-156, 1977.
261
82. Fine A, Summer DJ. Determination of acetylator status
in uraemia. Br J Clin Pharmacolf 2, 475-476, 1975.
83. Fishbein E, Alarcon-Segovia D. Slow acetylation
phenotype in systemic lupus erythematosus. Arthr
Rheumat f 22. 95-96, 1979.
84. Foad B, Litwin A, Zimmer H, Hess EV. Acetylator
phenotype in systemic lupus erythematosus. Arthr
Rheumat f 20. 815-818, 1977.
85. Gachályi B, Vas À, Hajós P, Káldor A. Acetylator
phenotypes: effect of age. Eur J Clin Pharmacol,
26, 43-45, 1984.
86. Gelber R, Peters JH, Gordon GR, Glazko AJ, Levy L. The
polymorphic acetylation of dapsone in man. Clin
Pharmacol Therf 12, 225-238, 1971.
87. Girling DJ. The hepatic toxicity of antitubercular
regimes containing isoniazid, rifampicin and
pyrazinamide. Tubercle. 59, 13-32, 1978.
IIí/fi
262
88. Glowinski IB, Radtke HE, Weber WW. Genetic variation
in N-acetylation of carcinogenic arylamines by human
and rabbit liver. Molec Pharmacol. 14. 940-949,
1978.
89. Goldstein PD, Alpers DH, Keating JT. Sulphapyridine
metabolites in children with inflammatory bowel
disease receiving sulphasalazine. J Pediatr. 95,
638-640, 1979.
90. Graham JB, Falls VWMC, Winters RW. Familial
hypophosphatemia with vitamin D resitant rickets. II.
Three additional kindreds of the sex-linked dominant
type with a genetic analysis of four such families.
Amer J Human Genet. 11. 311, 1959.
91. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation
of a caffeine metabolite. Clin Pharmacol Ther, 33,
355-359, 1983.
92. Grant DM, Tang BK, Kalow W. Variability in caffeine
263
metabolism. Clin Pharmacol Therf 33, 591-602,
1983.
93. Grant DM, Tang BK, Kalow W. A simple test for
acetylator phenotype using caffeine. Br J Clin
Pharmacol. 17, 459-464, 1984.
94. Gronhagen-Riska C, Heistrom PE, Froseth B.
Predisposing factors in hepatitis induced by
isoniazid-rifampicin treatment of tuberculosis. Am
Rev Respir Pis. 118. 461-466, 1978.
95. Hall S. Evaluation of the sulphadimidine acetylator
phenotyping test in a patient with reduced renal
function. Acta Med Scand. 209, 505-507, 1981.
96. Hanson A, Mclander A, Wahlin , Boll E. Acetylator
phenotyping: a comparison of the isoniazid and dapsone
tests. Eur J Clin Pharmacol. 20f 233-234, 1981.
97. Harland SJ, Facchini V, Timbrell JA. Hydralazine-
.e*>;
264
induced lupus erythematosus-1ike syndrome
in a patient of the rapid acetylator phenotype. Br
Med J. 281. 273-274, 1980.
98. Harris JW. The Red Cell. Harvard University Press.
Cambridge, 1970.
99. Harris H, Hopkinson DA, Luffman J. Enzyme diversity
in human populations. Ann N Y Acad Scif 151. 232-242,
1968.
100. Horai Y, Ishizaki T. Pharmacogenetics and its
clinical implications: N-acetylation polymorphism.
Rational Drug Therapy. 21. 10-17, 1987.
101. Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama K,
Iguchi S. Isoniazid disposition, comparison of
isoniazid phenotyping methods in and acetylator
distribution of Japanese patients with idiopathic
sistemic lupus erytheraatosus and control subjects. Br
J Clin Pharmacol. 13., 361-374, 1982.
265
102. Horai Y, Ishizaki T. N-acetylation polymorphism of
dapsone in a Japanese population. Br J Clin
Pharmacol. 25, 487-494, 1988.
103. Horai Y, Zhou H, Zhang L, Ishizaki T. N-acetylation
phenotyping with dapsone in a mainland Chinese
population. Br J Clin Pharmacol, 25, 81-87, 1988.
104. Horai Y, Ishizaki T. Pharmacogenetics and its
clinical implications .Partll. Oxidation polynorphism.
Rational Drug Therf 22. 6-1, 1988.
105. Hunyor SN. Hydralazine and beta-blockade in
refractory hypertension with characterization of the
acetylator phenotype. Austr N Z J Med, 5_, 530-536,
1975.
106. Hutchinson D, Wyld PJ. Sulphasalazine-induced
agranulocytosis. N Z Med J, 96. 520-521,
1983.
266
107. Idle JR, Mahgoub A, Lancaster R, Smith RL.
Hypotensive response to debrisoquine and
hydroxylation phenotype. Life Sci. 22, 979-984,
1978.
108. Idle JR, Smith RL. Polimorphism of oxidation at
carbon centers of drugs and their clinical
significance. Drug Metab Rev, 9_, 301-317, 1979.
109. Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO,
Bababunmi EA. Some observations on the oxidation
phenotype status of Nigerian patients presenting with
cancer. Cancer Letters, 11, 311-338, 1981.
110. Idle JR, Gates NS, Shah RR, Smith RL. Is there a
genetic predisposition to phenphormin-induced lactic
acidosis? Br J Clin Pharmacol. 11, 418P-419P,
1981.
111. Idle JR, Dates NS, Shah RR, Smith RL. Protecting poor
metabolisers: a group at risk of adverse reactions.
Lancet. 1, 1388, 1983.
267
112. Idle JR, Ritchie JC, Smith RL. Oxidation phenotype
and metiamide metabolism. Br J Pharmacol, 66,
432P, 1979.
113. Idle JR, Sloan TP, Smith RL, Wakile LA. Application
of the phenotyped panel approach to the detection of
polymorphism of drug oxidation in man. Br J
Pharmacol. 66. 430P-431P, 1980.
114. Inaba T, Otton SV, Kalow W. Deficient metabolism of
debrisoquine and sparteine. Clin Pharmacol Ther.
27., 547-549, 1980.
115. Inaba T, Otton SV, Kalow W. Debrisoquine
hydroxylation capacity: problems of assessment in
two populations. Clin Pharmacol Therf 29,
218-223, 1981.
116. Inaba T, Vinks A, Otton SW, Kalow W. Comparative
pharmacogenetics of sparteine and debrisoquine. Clin
Pharmacol Ther. 3_3., 394-399, 1983.
268
117. Inaba T, Jurima M, Nakano M, Kalow W. Mephenytoin and
sparteine pharmacogenetics in Canadian Caucasians.
Clin Pharmacol Ther. 36. 670-676, 1984.
118. Inaba T, Jorge LF, Arias TD. Mephenytoin
hydroxylation in the Cuna amerindians of Panama. Br
J Clin Pharmacol. 25. 75-79, 1988.
119. Ishizaki T, Horai Y, Koya G, Matsuyama K, Iguchi S.
Acetylator phenotype and metabolic disposition of
isoniazid in Japanese patients with systemic lupus
erythematosus. Arthr Rheumatf Z.4 r 1245-1254,
1981.
120. Islam SI, Idle JR, Smith RL. The polymorphic
4-hydroxylation of debrisoquine in a Saudi Arab
population. Xenobiotica. 10f 819-825, 1980.
121. Jack DB, Kendall MJ. Beta-blockers and debrisoquine
metaboliser status. Lancet, JL, 741, 1982.
269
122. Jack DB, Wilkins N, Quarterman CP. Lack of evidence
for polymorphism in metoprolol metabolism. Br J Clin
Pharmacol. 16. 188-190, 1983.
123. Johansson E, Mustakallio KK, Mattila MJ. Polymorphic
acetylator phenotype and systemic lupus erythematosus,
Acta Med Scand. 210. 193-196, 1981.
124. Johnstone EC, Marsh W. The relationship between
response to phenelzine and acetylator status in
depressed patients. Proc Royal Soc Medf 66f
947-949, 1973.
125. Jounela AJ, Pasanen M, Matilla MJ. Acetylator
phenotype and the antihypertensive response to
hydralazine. Acta Med Scand. 197f 303-306, 1975.
126. Jurima M, Inaba T, Kalow W. Sparteine oxidation by
the human liver. Absence of inhibition by
mephenytoin. Clin Pharmacol Ther, 35, 426-428,
1984.
270
127. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS.
Assay and characterisation of debrisoquine
4-hydroxylase activity of microsomal fractions of
human liver. Br J Clin Phariaacol. 13, 637-645,
1982.
128. Kalow W. Pharmacoqenetics; heredity and the response
to drugs. WB Saunders. Philadelphia, 1962.
129. Kalow W. Topics in pharmacogenetics. Ann NY Acad Sci,
179. 654-659, 1971.
130. Kalow W. Ethnic differences in drug metabolism. Clin
Pharmacokin, 7., 373-400, 1982.
131. Kappas A, Bradlow HL, Gilette PN, Levere RD,
Gallagher TF. A defect of steroid hormone metabolism
in acute intermittent porphyria. Fed Proc. 31f 1293,
1972.
132. Karim AKMB, Price Evans DA. Polymorphic acetylation
of nitrazepam. J Med Genet, 13. 17-19, 1976.
271
133. Kellerman G, Kellerman ML, Horning MG, Stafford M.
Elimination of antipyrine and benzo(a)pyrene
metabolism in cultured human lymphocytes. Clin
Pharmacol Ther. 20. 72-80, 1976.
134. Kirkraan HN. Glucose-6-phosphate dehydrogenase
variants and drug-induced hemolysis. Ann NY Acad
Sci. 151. 753, 1968.
135. Kitchin I, Tremblay J, Andre J, Dring LG, Idle JR,
Smith RL, Williams RT. Individual and interspecies
interaction in the metabolism of the hallucinogen
4-methoxyamphetamine. Xenobioticaf 9_, 397-404,
1979.
136. Kleinbloesen CH, Van Brummelen P, Faber H, Danhof M,
Vermeulen NPE, Breimer DD. Variability in nifedipine
pharmacokinetics and dynamics: a new oxydation
polymorphism in man. Biochem Pharmacolf 33.
3721-3724, 1984.
272
137. Kroemer HK, Mikus G, Kronbach T, Meyer VA, Eichelbaum M.
In vitro characterization of the human cytocrome P450
involved in polymorphic oxidation of propafenone. Clin
Pharmacol Ther. 45. 28-33, 1989.
138. Kong I, Devonshire HW, Cooper M, Sloan TP, Idle JR,
Smith RL. The influence of oxidation phenotype on
phenacetin metabolism and haemotoxicity. Br J Clin
Pharmacol. 13. 275P-276P, 1982.
139. Kupfer A, Dick B, Preisig R. Polymorphic mephenytoin
hydroxylation in man: a new phenotype in the genetic
control of hepatic drug metabolism. Hepatolocfv.
81, 34, 1981.
140. Kupfer A, Schmid B, Preisig R, Pfaff G.
Dextromethorphan as a safe probe for debrisoquine
hydroxylation polymorphism. Lancet, 2., 517-518,
1984.
141. Kutt H. Biochemical and genetic factors regulating
273
Dilantin metabolism in man. Ann NY Acad Scif
179. 704-722, 1971.
142. Kutt H, Brennan R, Dehejia H, Verebely K.
Diphenylhydantoin intoxication. A complication of
isoniazid therapy. Am Rev Respir Disf 101, 377-384,
1970.
143. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient
co-hydroxylation as a cause of diphenylhydantoin
toxicity. Neurology. 14, 542-548, 1964.
144. Ladero JM, Arroyo A. Envejecimiento y fenotipo
acetilador hepático. Rev Iberoamer Invest Clin.
2, 21-26, 1983.
145. Ladero JM, Arrojo A, de Salamanca RE, Gomez M, Cano
F, Alfonso M. Hepatic acetylator phenotype in
diabetes mellitus. Ann Clin Res. 14, 187-189,
1982.
274
146. Ladero JM, Arrojo A, Gilsanz V. Acetilación hepática
en la población española. Gastroenterol Hepatol.
2., 236-240, 1979.
147. Ladero JM, Fernández MJ, Jiménez LC. Influencia del
sexo, la edad y la pigmentación corporal sobre el
polimorfismo acetilador. An Med Intern
(Madrid). 5, 241-244, 1988.
148. Ladero JM, Fernández HJ, Palmeiro R, Muñoz JJ, Jara C,
Lázaro C, Pérez-Manga G. Hepatic acetylator polymorphism
in breast cancer patients. Oncology, 44. 341-344, 1987.
149. Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg
MM. Antibodies to nuclear antigens in patients
treated with procainamide or acetylprocainamide.
N Encfl J Med. 301. 1382-1385, 1979.
150. Langston JW, Forno LS, Rebert CS, Irwin I. Selective
nigral toxicity after systemic administration of
l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine (MPTP).
Brain Res. 292. 390-394, 1984.
275
151. Langston JW, Ballard P. Parkinsonism induced by
l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP):
implications for treatment and the pathogenesis of
Parkinson's disease. Can J Neurol Scif 11 (suppl),
160-165, 1984.
152. Langston JW. Closer to Parkinson's disease: MPTP and
the aging nervous system. Trends Pharmacol Scif
81, 7-8, 1987.
153. Larsson R, Karlberg BE, Norlander B, Wirsen A.
Prizidilol, an antihypertensive with precapillary
vasodilator and beta-adrenoceptor blocking actions in
primary hypertension. Clin Pharmacol Ther, 29,
588-593, 1981.
154. Larsson R, Karlsson E, Molin L. Spontaneous systemic
lupus erythematosus and acetylator phenotype. Acta
Med Scand. 201. 223-226, 1977.
155. Lawson DH, Henry DA, Lowe J, Reavey P, Rennie JA,
276
Solomon A. Acetylator phenotype in spontaneous SLE
and rheumatoid arthritis. Ann Rheum Pis, 38.
171-173, 1979.
156. Leclercq V, Desager JP, van Nienwenhuyze Y, Harvengt
C. Prevalence of drug hydroxylator phenotypes in
Belgium. Eur J Clin Pharmacol, 33, 439-440, 1987.
157. Lee EJ, Lee LKH. A simple pharmacokinetic method for
separating the three acetylation phenotypes: a
preliminary report. Br J Clin Pharmacolf 13.
375-378, 1982.
158. Leden I, Hanson A, Melander A, Sturfelt G, Svensson
B, Wahlin-Boll E. Varying distribution of acetylation
phenotypes in RA patients with and without Sjogren's
syndrome. Scand J Rheumf 10, 253-255, 1981.
159. Lennard MS, Freestone S, Ramsay LE, Tucker GT, Woods
HF. Oxidation phenotype and beta-blockers. N Engl J
Med. 308. 965, 1983.
277
160. Lennard MS, Silas JH, Smith AJ, Tucker GT.
Determination of debrisoquine and its 4-hydroxy
metabolite in biological fluids by gas chromatography
with flame-ionisation and nitrogen-selective detection.
J Chromatr 133. 161-166, 1977.
161. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker
GT, Wood HF. Oxydation phenotype - a major
determinant of metoprolol metabolism and response.
N Encrl J Med. 303. 1558-1560, 1982.
162. Lennard MS, Silas JH, Freestone S, Trevethick J.
Defective metabolism of metoprolol in poor
hydroxylators of debrisoquine. Br J Clin Pharmacol.
14, 301-303, 1982.
163. Lennard MS, Jackson PR, Freestone S, Tucker GT,
Ramsay LE, Woods HF. The relationship between
debrisoquine oxidation phenotype and the
pharmacokinetics and pharmacodynamics of propranolol.
Br J Clin Pharmacol. 17. 679-685, 1984.
278
164. Lennard MS, Tucker GT, Silas MD, Freestone S, Ramsay
LE, Woods HF. Differential stereoselective metabolism
of metoprolol in extensive and poor debrisoquine
metabolizers. Clin Pharmacol Ther. 34. 732-737,
1983.
165. Lennard MS, Tucker GT, Woods HF. The polymorphic
oxidation of /3-adrenoceptor antagonists. Clinical
pharmacokinetic considerations. Clin Pharmacokin,
11. 1-17, 1986.
166. Lennard MS, Tuccker GT, Woods HF, Silas JH, lyun ÀO.
Stereoselective metabolism of metoprolol-relationship
to debrisoquine oxydation phenotype. Br J Clin Pharmacol,
17, 1989.
167. Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden
LH, Jusko WJ. Clinical pharmacokinetics of
procainamide infusions in relation to acetylator
phenotype. J Pharmacokin Biopharm, 7_, 69-85, 1979.
279
168. Lou Y-Ch, Ying L, Bertilsson L, Sjqvist F. Low
frequency of slow debrisoquine hydroxylation in a
Chinese population. Lancet, 2., 852-853, 1987.
169. Lower Jr GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE,
Bryan GT. N-acetyltransferase phenotype and risk in
urinary bladder cancer. Approaches in molecular
epidemiology. Environm Health Perspect. 29,
71-79, 1979.
170. Lunde PKM, Frislid K, Hansteen V. Disease and
acetylation polymorphism. Clin Pharmacokin. 2.,
182-197, 1977.
171. Macklon AF, Savage RL, Rawlins MD. Gilbert's syndrome
and drug metabolism. Clin Pharmacokin, 4., 223-232,
1979.
172. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL.
Polymorphic hydroxylation of debrisoquine in man.
Lancet. 2., 584-586, 1977.
280
173. Mahgoub A, Idle JR, Smith RL. A population and
familial study of the defective salicylic
hydroxylation of debrisoquine among Egyptians.
Xenobiotica. 9., 51-56, 1979.
174. Mansilla-Tinoco R, Harland SJ, Ryan PJ, Berstein RM,
Dollery CT, Hughes GRV, Bulpitt CJ, Morgan A, Jones
JM. Br Med J. 284. 936-939, 1982.
175. March P. Metabolismo de la isoniazida. Tesis
doctoral. Barcelona, 1966.
176. Marsden CD. Neurotransmitters and CNS disease. Basal
ganglia disease. Lancet, 2, 1141-1147, 1982.
•i-111. Marshall EF, Mountjoy CQ, Campbell 1C, Garside RF,
Leitch IM, Roth M. The influence of acetylator
phenotype on the outcome of treatment with
phenelzine, in a clinical trial. Br J Clin
Pharmacol. 6, 247-254, 1978.